|41.63||+3.00||+7.77%||Vol 1.12M||1Y Perf -53.12%|
|Jan 27th, 2023 16:00 DELAYED|
|- -||0.19 0.46%|
|Target Price||109.30||Analyst Rating||Strong Buy 1.36|
|Potential %||162.55||Finscreener Ranking||★★★+ 52.07|
|Insiders Trans % 3/6/12 mo.||-/-/-100||Value Ranking||★★★ 51.46|
|Insiders Value % 3/6/12 mo.||-/-/-100||Growth Ranking||★★★+ 54.55|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-100||Income Ranking||— -|
|Price Range Ratio 52W %||12.69||Earnings Rating||Strong Buy|
|Market Cap||3.59B||Earnings Date||23rd Feb 2023|
Today's Price Range
5 Year PE Ratio Range
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||23rd Feb 2023|
|Estimated EPS Next Report||-1.38|
|EPS Growth Next 5 Years %||13.20|
|Avg. Weekly Volume||1.34M|
|Avg. Monthly Volume||1.12M|
|Avg. Quarterly Volume||1.12M|
Intellia Therapeutics Inc. (NASDAQ: NTLA) stock closed at 41.63 per share at the end of the most recent trading day (a 7.77% change compared to the prior day closing price) with a volume of 1.12M shares and market capitalization of 3.59B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 312 people. Intellia Therapeutics Inc. CEO is John M. Leonard.
The one-year performance of Intellia Therapeutics Inc. stock is -53.12%, while year-to-date (YTD) performance is 19.32%. NTLA stock has a five-year performance of 68.47%. Its 52-week range is between 32.435 and 104.87, which gives NTLA stock a 52-week price range ratio of 12.69%
Intellia Therapeutics Inc. currently has a PE ratio of -6.50, a price-to-book (PB) ratio of 3.94, a price-to-sale (PS) ratio of 81.39, a price to cashflow ratio of 17.80, a PEG ratio of 2.32, a ROA of -39.90%, a ROC of -42.33% and a ROE of -50.15%. The company’s profit margin is -%, its EBITDA margin is -819.20%, and its revenue ttm is $38.55 Million , which makes it $0.45 revenue per share.
Of the last four earnings reports from Intellia Therapeutics Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-1.38 for the next earnings report. Intellia Therapeutics Inc.’s next earnings report date is 23rd Feb 2023.
The consensus rating of Wall Street analysts for Intellia Therapeutics Inc. is Strong Buy (1.36), with a target price of $109.3, which is +162.55% compared to the current price. The earnings rating for Intellia Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Intellia Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Intellia Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 14.46, ATR14 : 2.46, CCI20 : 171.59, Chaikin Money Flow : 0.25, MACD : -0.21, Money Flow Index : 55.77, ROC : 10.10, RSI : 60.32, STOCH (14,3) : 99.24, STOCH RSI : 1.00, UO : 67.84, Williams %R : -0.76), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Intellia Therapeutics Inc. in the last 12-months were: David Lebwohl (Option Excercise at a value of $0), Glenn Goddard (Option Excercise at a value of $0), John M. Leonard (Option Excercise at a value of $0), Laura Sepp-Lorenzino (Option Excercise at a value of $0)
Mon, 09 Jan 2023 04:15 GMT Intellia Therapeutics (NTLA) Has a New Rating from SVB Securities- TipRanks. All rights reserved.
Mon, 19 Sep 2022 12:45 GMT Intellia Therapeutics (NTLA) Receives a Buy from SVB Securities- TipRanks. All rights reserved.
Fri, 16 Sep 2022 21:05 GMT Intellia Therapeutics (NTLA) Receives a Buy from Chardan Capital- TipRanks. All rights reserved.
Fri, 05 Aug 2022 12:35 GMT Intellia Therapeutics (NTLA) Receives a Hold from BMO Capital- TipRanks. All rights reserved.
Thu, 04 Aug 2022 22:45 GMT Intellia Therapeutics (NTLA) Gets a Buy Rating from Chardan Capital- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.